Concurrent Ocular and Dermatologic Toxicities Associated With Docetaxel Chemotherapy

Area of Science:

• Oncology
• Ophthalmology
• Dermatology

Background:

• Docetaxel is a chemotherapy agent used for various cancers.
• Ocular and dermatologic toxicities from docetaxel are rare but can be severe.
• Limited literature exists on managing combined ocular and dermatologic toxicities.

Purpose of the Study:

• To report two cases of combined ocular and dermatologic toxicities from docetaxel.
• To highlight the importance of prompt diagnosis and management of these rare adverse events.

Main Methods:

• Case report of two patients receiving docetaxel-containing chemotherapy.
• Detailed description of clinical presentation, treatment, and outcomes.
• Review of existing literature on docetaxel-induced toxicities.

Main Results:

• Two patients developed concurrent severe ocular (epiphora, discharge, lesions) and dermatologic (rash, sores) toxicities after docetaxel.
• Both cases showed a preceding milder reaction one cycle prior to severe presentation.
• Symptoms included eyelid margin sores, facial rash, and widespread desquamating rash with ocular discharge.

Conclusions:

• Combined ocular and dermatologic toxicities are rare but serious adverse events associated with docetaxel.
• A sequential presentation of milder symptoms followed by severe reactions was observed.
• Multidisciplinary care involving oncology and ophthalmology is crucial for effective management and minimizing patient morbidity.